Fred Alger Management LLC Has $2.02 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• Fred Alger Management LLC increased its holdings in GSK PLC by 16.7% during the first quarter, acquiring an additional 7,390 shares and valuing its total stake at $2.02 million.
• GSK reported an EPS of $1.23 for the last quarter, beating estimates by $0.11, with revenue reaching $10.64 billion compared to expected $7.92 billion.
• The company declared a quarterly dividend of $0.4206 per share, translating to an annualized dividend of $1.68 and a yield of 4.1%.

Fred Alger Management LLC grew its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 16.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 51,693 shares of the pharmaceutical company's stock after purchasing an additional 7,390 shares during the period. Fred Alger Management LLC's holdings in GSK were worth $2,020,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in GSK. Dodge & Cox boosted its stake in shares of GSK by 14.9% in the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares in the last quarter. Voloridge Investment Management LLC raised its holdings in shares of GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock valued at $73,222,000 after buying an additional 2,016,795 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of GSK in the first quarter valued at about $67,267,000. Woodline Partners LP bought a new position in shares of GSK in the fourth quarter valued at about $36,665,000. Finally, Miller Howard Investments Inc. NY raised its holdings in shares of GSK by 138.4% in the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after buying an additional 955,891 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on GSK. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Trading Down 1.6%

NYSE:GSK traded down $0.67 on Friday, hitting $40.81. 4,741,956 shares of the stock were exchanged, compared to its average volume of 3,553,270. The stock has a market capitalization of $83.12 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 2.07 and a beta of 0.53. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $43.62. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company's 50-day moving average price is $38.74 and its 200 day moving average price is $38.46.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Friday, August 15th. GSK's payout ratio is currently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.